Abstract: This invention provides, among other things, novel compounds useful for treating bacterial infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.

Abstract: Disclosed herein are methods and kits for identifying a subject as having leukemia. Also provided herein are methods and kits for determining a leukemia subtype in subject. Further provided herein are methods and kits for determining the prognosis of a subject having leukemia and for determining the progression of leukemia in a subject.

Abstract: Disclosed herein are methods of increasing the expression rate of epigenetic markers such as ELOVL2, KLF14, and PENK with administration of a therapeutic agent (e.g., vitamin C or its derivatives, analogs, metabolites, prodrugs, or pharmaceutically acceptable salts thereof). Also described herein are methods of modulating the methylation pattern of epigenetic markers such as ELOVL2, KLF14, and PENK with administration of a therapeutic agent (e.g., vitamin C or its derivatives, analogs, metabolites, prodrugs, or pharmaceutically acceptable salts thereof).

Abstract: The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.

Abstract: In one embodiment, a computing device receives receive a request for particular content associated with an application. The device may determine, based on a first recycling policy associated with a first recycler, that the first recycler associated with the application includes a display object that is capable of being used for containing the particular content. The device may encapsulate the display object with the particular content in a wrapper object and return the wrapper object encapsulating the display object in response to the request. The device may receive an indication that the display object is no longer needed, and extract the display object from the wrapper object. The display object may be stored in the first recycler. The wrapper object without the display object may be disposed in accordance with a second recycling policy associated with a second recycler associated with an operating system of the computing device.

Abstract: The compounds are of the class of 3,7 substituted benzoxaboroles, useful for killing and/or inhibiting the growth of microorganisms.

Abstract: An artificial cornea is fabricated by separately culturing live stromal cells, live corneal endothelial cells (CECs) and live corneal epithelial cells (CEpCs), and 3D bioprinting separate stromal, CEC and CEpC layers to encapsulate the cells into separate hydrogel nanomeshes. The CEC layer is attached to a first side of the stromal layer and the CEpC layer to a second side of the stromal layer to define the artificial cornea.

Abstract: Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.

Abstract: A computing device receives a request for content for a content layout in a displayable region of a screen associated with the device. The device determines, based on application-tailored recycling policies, whether a recycler includes a display object that is suitable for recycling or re-use. If it does not, the device creates the display object and fills it with the content. If it does, and if the display object contains the content, the device updates elements of the display object as needed; otherwise, if the display object does not contain the content, the device fills the display object with the content and returns it. The recycling or re-using may also be performed with sub-elements of a display object, some of which may comprise nested display objects.

Abstract: The disclosure generally relates to compositions and uses thereof to treat vision disorders that affect the normal function of the lens in the eye in a subject having or at risk of developing such vision disorders.

Abstract: The invention provides an isolated limbal stem or progenitor cell (LSC) population or LSC-like population comprising a chemically synthesized, recombinant or isolated nucleic acid encoding PAX6 integrated into a chromosome, or alternatively, not integrated remaining as an extrachromosomal genetic material, wherein the isolated LSC population is substantially free of non-LSC cells or wherein the LSC-like population is substantially free of non-LSC-like cells, or wherein the isolated LSC or LSC-like population is substantially free of non-LSC and non-LSC-like cells and uses thereof.

Abstract: Described herein are compounds that inhibit or prevent protein aggregation, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with protein aggregation.

Abstract: Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.

Abstract: An embolic coil delivery assembly is disclosed. The delivery system may include a tubular member having a distal portion, a proximal portion and a lumen extending therein. The system may further include a tip member secured to the tubular member. The tip member may include a distal portion and a bonding portion. The bonding portion may include a bonding surface. The system may also include an embolic coil releasably disposed within the distal portion of the tip member. The distal portion of the tubular member may extend over the bonding portion of the tip member. The bonding surface may be configured to mechanically interlock with the tubular member.

Abstract: Provided are compounds useful for controlling endoparasites both in animals and agriculture. Further provided are methods for controlling endoparasite infestations of an animal by administering an effective amount of a compound as described above, or a pharmaceutically acceptable salt thereof, to an animal, as well as formulations for controlling endoparasite infestations using the compounds described above or an acceptable salt thereof, and an acceptable carrier.

Abstract: Methods and systems for autofocusing of an imaging system are presented. Provided is an imaging system and an optical interferometry system for generating one or more images corresponding to a target region in a subject. The method provides calibration information that identifies a focal position of the optical interferometry system corresponding to a determined focal position of the imaging system. A subsequent focal position of the imaging system is determined for generating a desired image corresponding to at least one of another target region in the subject and another position of the target region relative to the imaging system based on the calibration information.

Abstract: Disclosed herein are methods and pharmaceutical compositions for the treatment of glaucoma by interfering with expression of genes, such as p16, in cells of the eye. These methods and compositions employ nucleic acid based therapies.

Abstract: This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.

Abstract: The present invention provides sterols and uses thereof to treat vision disorders. In one embodiment, composition comprising pharmaceutically effective amount of lanosterol is used to treat and/or prevent vision disorders in a subject. In another embodiment, composition comprising pharmaceutically effective amount of lanosterol is used to treat cataract or blindness/impaired vision in a subject. In yet another embodiment, composition comprising lanosterol is used to dissolve amyloid-like fibrils of crystallin proteins.

Abstract: This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.